Clinical Profile and Outcome of Postthymectomy versus Non-Thymectomy Myasthenia Gravis Patients in the Philippine General Hospital: A 6-Year Retrospective Study

被引:10
作者
De Roxas, Ranhel C. [1 ]
Bagnas, Marjorie Anne C. [1 ]
Baldonado, Jobelle Joyce Anne R. [2 ]
Rivera, Jonathan P. [3 ]
Roxas, Artemio A. [1 ]
机构
[1] Philippine Gen Hosp, Dept Neurosci, Manila, Philippines
[2] Philippine Gen Hosp, Dept Surg, Manila, Philippines
[3] Philippine Gen Hosp, Dept Pathol, Manila, Philippines
来源
FRONTIERS IN NEUROLOGY | 2016年 / 7卷
关键词
myasthenia gravis; thymoma; non-thymomatous; thymectomy; REMISSION; SURGERY;
D O I
10.3389/fneur.2016.00096
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Myasthenia gravis is an autoimmune neuromuscular disorder characterized by the production of abnormal autoantibodies directed against the receptors present in the neuromuscular junction. It has been the standard practice to offer thymectomy in all generalized myasthenia gravis patients despite the lack of robust evidence. Objectives: The objectives of this study are to describe the clinical profile and differentiate the clinical outcomes of thymectomy versus non-thymectomy and thymomatous versus non-thymomatous myasthenia gravis patients in the Philippine General Hospital. Methodology: Between 2009 and 2014, a total of 69 postthymectomy and 16 non-thymectomy patient records were successfully retrieved. The demographic characteristics, surgical approach, and histopathologic results were obtained. The clinical outcome after 6 months or 1 year-follow-up was also determined and grouped according to the following: (1) complete remission, (2) pharmacological remission, (3) no clinical change, (4) worsening symptoms, and (5) mortality. Results: Majority of the patients were females (68.0%) with a mean age of 39.8 years and a mean duration of myasthenic symptoms of 21 months. Using the Myasthenia Gravis Foundation of America classification, 54.1% of patients fell under Class II and 48.2% of them presented with generalized weakness. In this study, 60.8% of postthymectomy myasthenia gravis patients had either complete remission or pharmacologic remission compared with 12.5% among non-thymectomy patients (p-value <0.001). No significant difference in the clinical outcome was found between thymomatous and non-thymomatous myasthenia gravis after thymectomy (p-value = 0.29). Conclusion: This study showed that both thymomatous and non-thymomatous myasthenia gravis patients who underwent thymectomy had a higher incidence of complete stable remission and pharmacologic remission as compared with myasthenia gravis patients who did not undergo thymectomy.
引用
收藏
页数:7
相关论文
共 37 条
  • [21] Effects of thymectomy on late-onset myasthenia gravis without thymoma
    Kawaguchi, Naoki
    Kuwabara, Satoshi
    Nemoto, Yuko
    Fukutake, Toshio
    Arimura, Kimiyoshi
    Sarne, Mitsuhiro
    Hattori, Takamichi
    [J]. CLINICAL NEUROLOGY AND NEUROSURGERY, 2007, 109 (10) : 858 - 861
  • [22] Robotic thymectomy in patients with myasthenia gravis: neurological and surgical outcomes
    Keijzers, Marlies
    de Baets, Marc
    Hochstenbag, Monique
    Abdul-Hamid, Myrurgia
    zur Hausen, Axel
    van der Linden, Marcel
    Kuks, Jan
    Verschuuren, Jan
    Kessels, Fons
    Dingemans, Anne-Marie C.
    Maessen, Jos
    [J]. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2015, 48 (01) : 40 - 45
  • [23] Factors predicting surgical outcome of thymectomy in myasthenia gravis: A 16-year experience
    Kumar, Nilkamal
    Verma, A. K.
    Mishra, A.
    Agrawal, G.
    Agrawal, A.
    Misra, U. K.
    Mishra, S. K.
    [J]. ANNALS OF INDIAN ACADEMY OF NEUROLOGY, 2011, 14 (04) : 267 - 271
  • [24] Nationwide Population-Based Epidemiological Study of Myasthenia Gravis in Taiwan
    Lai, Chien-Hsu
    Tseng, Hung-Fu
    [J]. NEUROEPIDEMIOLOGY, 2010, 35 (01) : 66 - 71
  • [25] Liu W, 2002, CHINESE MED J-PEKING, V115, P235
  • [26] Current and emerging therapies for the treatment of myasthenia gravis
    Mantegazza, Renato
    Bonanno, Silvia
    Camera, Giorgia
    Antozzi, Carlo
    [J]. NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2011, 7 : 151 - 160
  • [27] Prognostic factors of remission in myasthenia gravis after thymectomy
    Mao, Zhifeng
    Hu, Xueqiang
    Lu, Zhengqi
    Hackett, Maree L.
    [J]. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2015, 48 (01) : 18 - 24
  • [28] Myasthenia gravis: clinical, immunological, and therapeutic advances
    Romi, F
    Gilhus, NE
    Aarli, JA
    [J]. ACTA NEUROLOGICA SCANDINAVICA, 2005, 111 (02): : 134 - 141
  • [29] Thymoma in Myasthenia Gravis: From Diagnosis to Treatment
    Romi, Fredrik
    [J]. AUTOIMMUNE DISEASES, 2011, 2011
  • [30] Corticosteroids for myasthenia gravis - art. no. CD002828.pub2
    Scheider-Gold, C
    Gajdos, P
    Toyka, KV
    Hohlfeld, RR
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2005, (02):